Elekta AB, commonly known as Elekta, is a leading innovator in the field of medical technology, headquartered in Stockholm, Sweden (SE). Founded in 1972, the company has established itself as a key player in the oncology and neurosurgery sectors, providing advanced solutions for cancer treatment and brain disorders.
Elekta's core offerings include state-of-the-art radiation therapy systems, software solutions for treatment planning, and comprehensive patient management tools. What sets Elekta apart is its commitment to precision and personalised care, utilising cutting-edge technology to enhance treatment outcomes.
With a strong presence in Europe, North America, and Asia, Elekta has achieved significant milestones, including numerous awards for innovation and excellence in healthcare. The company continues to lead the market, driven by its mission to improve the lives of patients worldwide through advanced medical solutions.
+62 vs industry average
Elekta’s score of 84 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Elekta?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Health Services has typical carbon intensity
Industry performance
The Health Services industry has increased its overall emissions by 7% since 2019
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Elekta's reported carbon emissions
In 2025, Elekta reported total carbon emissions of approximately 490.9 million kg CO2e, comprising 5,007,000 kg CO2e from Scope 1, 3,181,000 kg CO2e from Scope 2, and a significant 482,753,000 kg CO2e from Scope 3 emissions. This represents a decrease from 2024, where total emissions were approximately 541.5 million kg CO2e, and from 2023, which saw emissions of about 621.7 million kg CO2e. Elekta has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by FY2031, using FY2021 as the baseline. Additionally, the company plans to increase its annual sourcing of renewable electricity from 61% in FY2021 to 100% by FY2030. For Scope 3 emissions, Elekta targets a 55% reduction per radiotherapy cancer treatment course by FY2031, also from a FY2021 baseline. Furthermore, the company aims for 45% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by FY2026. These commitments align with the Science Based Targets initiative (SBTi) and reflect Elekta's dedication to sustainability and reducing its environmental impact.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Elekta’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Elekta yet.
Scope 3 top emissions categories
9 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Elekta
Frequently asked questions
Common questions about Elekta’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project